New York, Apr 29th, 2019 – Microbiosci, as a leading supplier focuses on providing global scientists with high quality products and satisfactory services to facilitate the investigation of microbial researches, recently announces the launch of its comprehensive industrial fermentation products which aims to satisfy GMP or high purity requirements in various industrial productions with advanced fermentation technologies.
At present, the fermentation process is considered an important technical asset to reduce dependence on chemicals and products produced by fossil fuels. Fermentation products are useful as pharmaceutical production as well as in the general industry, where some commercial chemicals are produced by fermentation, the rate of fermentation depends on the concentration of the microorganisms, as well as temperature, pH and aerobic fermentation oxygen. Product recovery typically involves the concentration of the dilute solution. Almost all commercially produced enzymes, such as lipases, invertases, and chymosins, are prepared by fermentation with genetically modified microorganisms.
Recombinant Pharmaceutical Protein Strains, as one of the featured products of Industrial Fermentation Products, is considered as biosafety and green process, and gives the ability to modify amino acid sequences and protein functions to better tune the product to achieve the desired function. Microbiosci provides our customers with E. coli and yeast cell factories.
E. coli is a popular platform, and both systems and related genetic methods have exceptionally high versatility compared to the subsequent Saccharomyces cerevisiae, adapting them to different production needs. In various potential cell factories, yeast has attracted great attention in drug-protein synthesis due to its single-cell and eukaryotic properties, ease of genetic manipulation, rapid growth, and post-translational modification.
Recombinant drugs are shifting from simple recombinant versions of natural products to more complex protein constructs, which are produced by a rational design process. On the other hand, the use of currently available synthetic biology tools such as CRISPR/Cas9 in yeast engineering will further assist researchers in manipulating yeast strains to produce highly secreted recombinant therapeutic proteins with desirable characteristics. In summary, currently available systems and synthetic biology tools can be applied to yeast engineering to improve the production of biopharmaceutical proteins.
As a division of Creative Biogene, Microbiosci is capable to satisfy the needs of our clients across more than 50 countries and districts with the accumulated experience and professional team. As a well-recognized industry leader, we will always devote to delivering medicine microbiology solutions to clinical, pharmaceutical and veterinary in order to promote the development of biotechnology.
Company Name: Creative Biogene
Contact Person: Marcia Brady
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States